kneat.com (TSE:KSI) Sets New 52-Week High – Should You Buy?

kneat.com, inc. (TSE:KSI)’s share price reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as C$6.53 and last traded at C$6.45, with a volume of 128055 shares. The stock had previously closed at C$6.39.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on KSI. Cibc World Mkts raised shares of kneat.com to a “strong-buy” rating in a report on Tuesday, October 29th. CIBC set a C$6.00 target price on shares of kneat.com and gave the company an “outperform” rating in a research note on Tuesday, October 29th.

kneat.com Price Performance

The firm has a 50-day moving average of C$5.81 and a 200-day moving average of C$5.08. The stock has a market cap of C$554.70 million, a PE ratio of -40.31, a PEG ratio of 597.67 and a beta of 1.08. The company has a debt-to-equity ratio of 95.14, a current ratio of 1.47 and a quick ratio of 1.50.

kneat.com (TSE:KSI) last announced its quarterly earnings data on Wednesday, November 6th. The company reported C$0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of C($0.05) by C$0.06. kneat.com had a negative net margin of 31.19% and a negative return on equity of 51.13%. During the same quarter last year, the company posted ($0.05) earnings per share. Research analysts predict that kneat.com, inc. will post -0.12 EPS for the current year.

kneat.com Company Profile

kneat.com, inc., together with its subsidiaries, designs, develops, and supplies software for data and document management within regulated environments in North America, Europe, and the Asia Pacific. The company offers the Kneat Gx platform, a configurable off-the-shelf application focused on validation lifecycle management and testing for biotechnology, pharmaceutical, and medical device manufacturing industries.